LDP

By Targets:	Apoptosis (4) Autophagy (4) Integrin (1) Lipoxygenase (2) NF-κB (4) PD-1/PD-L1 (1) Proteasome (4) Reference Standards (1) Small Interfering RNA (siRNA) (1)
By Research Areas:	Cancer (5) Inflammation/Immunology (4)
Oligonucleotides:	Human Pre-designed siRNA Sets (1) siRNAs (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99698

Lesabelimab LDP	PD-1/PD-L1	Inflammation/Immunology Cancer
Lesabelimab (LDP) is an immunoglobulin G1-kappa anti-CD274 monoclonal antibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor .

HY-10227

Bortezomib 180+ Cited Publications PS-341; LDP-341; NSC 681239	Proteasome NF-κB Apoptosis Autophagy	Cancer
Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity .

HY-10227R

Bortezomib (Standard) PS-341 (Standard); LDP-341 (Standard); NSC 681239 (Standard)	Reference Standards Proteasome NF-κB Apoptosis Autophagy	Cancer
Bortezomib (Standard) is the analytical standard of Bortezomib. This product is intended for research and analytical applications. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity .

HY-10227S

Bortezomib-d8 PS-341-d₈; LDP-341-d₈; NSC 681239-d₈	Proteasome NF-κB Apoptosis Autophagy	Cancer
Bortezomib-d₈ is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity .

HY-U00260

CMI977 LDP977	Lipoxygenase	Inflammation/Immunology
CMI977 is a potent 5-Lipoxygenase (5-LO) inhibitor.

HY-19205A

CMI-392 LDP-392	Lipoxygenase	Inflammation/Immunology
CMI-392 is a dual 5-lipoxygenese inhibitor and platelet-activating factor (PAF) receptor antagonist with IC₅₀s of 100 and 10 nM, respectively.

HY-P991604

MLN2201 YFC51.1; LDP-01	Integrin	Inflammation/Immunology
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .

HY-10227G

Bortezomib PS-341; LDP-341; NSC 681239	Proteasome NF-κB Apoptosis Autophagy	Cancer
Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity .

HY-RS03114

CPQ Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CPQ Human Pre-designed siRNA Set A contains three designed siRNAs for CPQ gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CPQ Human Pre-designed siRNA Set A CPQ Human Pre-designed siRNA Set A

Cat. No.	Product Name	Type

HY-10227G

Bortezomib (GMP) PS-341 (GMP); LDP-341 (GMP); NSC 681239 (GMP)	Fluorescent Dye
Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity .

Bortezomib (GMP)

PS-341 (GMP); LDP-341 (GMP); NSC 681239 (GMP)

Fluorescent Dye

Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity .

Cat. No.	Product Name	Type

HY-10227G

Bortezomib (GMP) PS-341 (GMP); LDP-341 (GMP); NSC 681239 (GMP)	Biochemical Assay Reagents
Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity .

Bortezomib (GMP)

PS-341 (GMP); LDP-341 (GMP); NSC 681239 (GMP)

Biochemical Assay Reagents

Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity .

Cat. No.	Product Name	Target	Research Area

HY-P99698

Lesabelimab LDP	PD-1/PD-L1	Inflammation/Immunology Cancer
Lesabelimab (LDP) is an immunoglobulin G1-kappa anti-CD274 monoclonal antibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor .

HY-P991604

MLN2201 YFC51.1; LDP-01	Integrin	Inflammation/Immunology
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .

Cat. No.	Product Name	Chemical Structure

HY-10227S

Bortezomib-d8
Bortezomib-d₈ is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83922

	LMNA Antibody (YA3619) FPL; IDC; LFP; CDDC; EMD2; FPLD; HGPS; LDP1; LMN1; LMNC; PRO1; CDCD1; CMD1A; FPLD2; LMNL1; CMT2B1	WB, IHC-P, ELISA	Human, Mouse, Rat
	LMNA Antibody (YA3619) is a mouse-derived and non-conjugated IgG1 antibody, targeting to LMNA. It can be applicated for WB, IHC-P, ELISA assays, in the background of human, mouse, rat.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-RS03114

CPQ Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CPQ Human Pre-designed siRNA Set A contains three designed siRNAs for CPQ gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Inhibitory Antibodies

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Name
Email *

	Sorry, but the email address you supplied was invalid.